Alfa Laval strengthens Flemingsberg – establishes itself in a growing city of the future

In May 2025, Alfa Laval moved into its new office and innovation center, spanning approximately 20,000 square meters, together with around 700 employees. At the same time, the restaurant K-märkt opened, further expanding the range of services available in Flemingsberg. The Royal Swedish Opera and Dramaten, Alfa Laval, Restaurant Billmans, and K-märkt all represent important pieces of the puzzle in the development of Flemingsberg.

It’s a warm May day when 700 Alfa Laval employees are welcomed to Flemingsberg with signs, balloons, and friendly faces guiding them to their new office. This will be their new workplace, located at the heart of one of Sweden’s largest urban development projects, with the ambitious goal of reaching 50,000 workers, 50,000 residents, and 50,000 visitors in Flemingsberg by 2050.

“We are very pleased to have established our new premises in Flemingsberg. This expansion represents a significant improvement for our employees, our operations, and our customers. Flemingsberg is now Alfa Laval’s hub for all development of separators within the marine, energy, food, and pharma sectors. We are also establishing our Innovation Centre for pharma here, further reinforcing our commitment to innovation and growth.”
– Peter Nielsen, Alfa Laval’s Site Manager for Flemingsberg and President of the Business Unit High Speed Separators

“We are very happy to welcome Alfa Laval to Flemingsberg and as a tenant of Fabege. Their presence strengthens the area’s position as a dynamic and innovative hub for research and development. We look forward to a continued successful collaboration that contributes to Flemingsberg’s ongoing growth and success.”
– Anna Nyberg, Head of Business Development at Fabege

Flemingsberg is not just a place you pass – it’s a place on the move.
Welcome to join us, too!

Published On: 3 December 2025
  • Martin Jönsson: “The time is ripe for a breakthrough in dementia treatment”

    Nearly 100,000 people in Sweden suffer from Alzheimer’s. Globally, about 30 million people are thought to have the disease. There is still no cure, but research is approaching a point where new drugs may become crucial. AlzeCure is one of the pharmaceutical companies that has made the most progress.

  • AlzeCure Pharma

    The stimulating environment with access to leading research in the area, and the positive climate on Campus Flemingsberg encourages exciting co-operation

  • Bactigard

    When we needed more space to establish an integrated facility for all our activities, including production, Flemingsberg was the natural choice

  • Biomedrex Genetics

    Thanks to great contacts, including Flemingsberg Science, we quickly got a place at Ana Futura in Flemingsberg.

  • Cellaviva: improving lives through stem cell technology

    Flemingsberg is a cluster for cell therapies that gives us proximity to partners, the clinical research and the trial clinic at Karolinska Hospital where many of the patients have received their treatment.